naftopidil has been researched along with Bladder Cancer in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Fukuhara, H; Gotoh, A; Kino, Y; Kurioka, R; Mabuchi, M; Matsunaga, W; Nakao, S; Shimizu, T; Tanaka, A; Yamaguchi, K; Yamamoto, M | 1 |
| Gotoh, A; Miyata, T; Nagaya, H; Nakagawa, YU; Oyama, T; Wada, Y | 1 |
| Gotoh, A; Kanno, T; Nagaya, H; Nishizaki, T | 1 |
3 other study(ies) available for naftopidil and Bladder Cancer
| Article | Year |
|---|---|
Identification of HUHS190, a human naftopidil metabolite, as a novel anti-bladder cancer drug.
Topics: Animals; Antineoplastic Agents; Female; Humans; Male; Mice; Naphthalenes; Piperazines; Structure-Activity Relationship; Urinary Bladder Neoplasms | 2020 |
Piperazine-based Alpha-1 AR Blocker, Naftopidil, Selectively Suppresses Malignant Human Bladder Cells via Induction of Apoptosis.
Topics: Adrenergic alpha-Antagonists; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Humans; Male; Mice, Nude; Naphthalenes; Piperazines; Tumor Burden; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2016 |
Antitumor action of α(1)-adrenoceptor blockers on human bladder, prostate and renal cancer cells.
Topics: Adrenergic alpha-1 Receptor Antagonists; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Humans; Kidney Neoplasms; Male; Naphthalenes; Piperazines; Prazosin; Prostatic Neoplasms; Urinary Bladder Neoplasms | 2012 |